30 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Article Searches
Arcadis NV (ARCAY) Is a Great Choice for 'Trend' Investors, Here's Why https://www.zacks.com/stock/news/2204413/arcadis-nv-arcay-is-a-great-choice-for-trend-investors-here-s-why?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2204413 Jan 02, 2024 - If you are looking for stocks that are well positioned to maintain their recent uptrend, Arcadis NV (ARCAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
NVS or LLY: Which Is the Better Value Stock Right Now? https://www.zacks.com/stock/news/2206412/nvs-or-lly-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2206412 Jan 05, 2024 - NVS vs. LLY: Which Stock Is the Better Value Option?
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High https://www.zacks.com/commentary/2211005/these-stocks-are-showing-relative-strength-as-s-p-500-stalls-near-record-high?cid=CS-ZC-FT-investment_ideas-2211005 Jan 16, 2024 - As investors, our job isn't to predict an unknowable future.
Novartis Ag (NVS) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/01/31/novartis-ag-nvs-q4-2023-earnings-call-transcript/?source=iedfolrf0000001 Jan 31, 2024 - NVS earnings call for the period ending December 31, 2023.
Euronav NV (EURN) Q4 2023 Earnings Call Transcript https://seekingalpha.com/article/4667181-euronav-nv-eurn-q4-2023-earnings-call-transcript?source=feed_sector_transcripts Feb 02, 2024 - Euronav NV (NYSE:NYSE:EURN) Q4 2023 Earnings Conference Call February 2, 2024 8:00 AM ETCompany ParticipantsAlexander Saverys - Chief Executive...
Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates https://www.zacks.com/stock/news/2220214/pharma-stock-roundup-pfe-mrk-nvo-sny-s-q4-earnings-fda-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2220214 Feb 02, 2024 - Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
KBC Group NV (KBCSY) Q4 2023 Earnings Call Transcript https://seekingalpha.com/article/4668916-kbc-group-nv-kbcsy-q4-2023-earnings-call-transcript?source=feed_sector_transcripts Feb 08, 2024 - KBC Group NV (OTCPK:KBCSY) Q4 2023 Earnings Conference Call February 8, 2024 3:30 AM ETCompany ParticipantsKurt De Baenst – Investor Relations ManagerJohan...
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529 Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414 Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293 Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.

Pages: 123

Page 1>